As of Wednesday close, PTC Therapeutics Inc.’s (NASDAQ:PTCT) stock was down -$0.7, moving down -1.75 percent to $39.40. The average number of shares traded per day over the past five days has been 526,640 shares. 3 times new highs have been achieved over the past 5 days, with a $2.01 gain in that time frame. In the last twenty days, the average volume was 712,005, while in the previous 50 days, it was 666,428.
Since last month, PTCT stock retreated -11.64%. Shares of the company fell to $33.25 on 11/04/22, the lowest level in the past month. A 52-week high of $55.58 was reached on 09/20/22 after having rallying from a 52-week low of $25.01. Since the beginning of this year, PTCT’s stock price has dropped by -1.08% or -$0.43, and marked a new high 19 times. However, the stock has declined by -29.11% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
PTCT stock investors should be aware that PTC Therapeutics Inc. (PTCT) stock had its last reported insider trading activity 37 days ago on Oct 18. Boulding Mark Elliott, the EXEC. VP AND CLO of the company, disposed of 299 shares for $55.06 on Oct 18. It resulted in a $16,462 divestment by the insider. Boulding Mark Elliott sold 6,602 shares at an average price of $55.00 on Oct 17. The insider now owns 61,110 shares following the transaction. On Sep 20, EXEC. VP AND CLO Boulding Mark Elliott sold 1,176 shares at $55.00 apiece. The transaction was valued at $64,680.
In the three months ended September 29, PTC Therapeutics Inc.’s quick ratio stood at 1.20, while its current ratio was 1.20, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 93.80% percent. In the year ended September 29, operating margins totaled -47.60%. Based on annual data, PTCT earned $506.26 million in gross profit and brought in $538.59 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -31.90%. Return on equity (ROE) for the past 12 months was 426.60%.
In PTC Therapeutics Inc.’s quarter-end financial report for September 29, it reported total debt of $282.75 million against cash and short-term investments of $184.01 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. PTCT’s revenue rose 36.1% to $165.53 million during the quarter, while net income inched up to $217.13 million. While analysts expected PTC Therapeutics Inc. to report -$1.24 quarterly earnings, the actual figure was -$1.53 per share, beating the consensus estimate by -23.40%. During the quarter, the company generated -$33.08 million in EBITDA. The liabilities of PTC Therapeutics Inc. were 1.8 billion at the end of its most recent quarter ended September 29, and its total debt was $415.03 million. The value of shareholders’ equity is $71.88 million.
This quick technical analysis looks at PTC Therapeutics Inc.’s (PTCT) price momentum. With a historical volatility rate of 36.76%, the RSI 9-day stood at 50.34% on 23 November.
With respect to its five-day moving average, the current PTC Therapeutics Inc. price is up by +5.38% percent or $2.01. At present, PTCT shares trade -13.69% below its 20-day simple moving average and -10.00% percent below its 100-day simple moving average. However, the stock is currently trading approximately -26.29% below its SMA50 and -9.76% below its SMA200.
Stochastic coefficient K was 83.57% and Stochastic coefficient D was 86.82%, while ATR was 2.00. Given the Stochastic reading of 78.95% for the 14-day period, the RSI (14) reading has been calculated as 45.51%. As of today, the MACD Oscillator reading stands at 0.94, while the 14-day reading stands at 2.12.
Jefferies launched its rating on PTC Therapeutics Inc. (NASDAQ: PTCT) to a Buy in a note to investors on September 12, 2022. PTC Therapeutics Inc. (PTCT) has been rated Overweight by analysts. According to 0 brokerage firms, PTCT is a sell, and 6 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate PTC Therapeutics Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $47.00, the current consensus forecast for the stock is $36.00 – $69.00. Based on these forecasts, analysts predict PTC Therapeutics Inc. (PTCT) will achieve an average price target of $51.46.